key: cord-0834165-tc13gzi6
authors: Sa‐ngiamsuntorn, Khanit; Hongeng, Suradej; Wongkajornsilp, Adisak
title: Development of Hepatocyte‐like Cell Derived from Human Induced Pluripotent Stem cell as a Host for Clinically Isolated Hepatitis C Virus
date: 2017-08-14
journal: Curr Protoc Stem Cell Biol
DOI: 10.1002/cpsc.35
sha: d0b66f3729fbb0c3f356bd20fc47a7dfaf16a6e3
doc_id: 834165
cord_uid: tc13gzi6

This unit describes protocols to develop hepatocyte‐like cells (HLCs) starting from mesenchymal stem cells (MSCs) as a natural host for hepatitis C virus (HCV). These include the preparation of MSCs from bone marrow, the reprogramming of MSCs into induced pluripotent stem cells (iPSCs), and the differentiation of iPSCs into HLCs. This unit also incorporates the characterization of the resulting cells at each stage. Another section entails the preparations of HCV. The sources of HCV are either the clinically isolated HCV (HCVser) and the conventional JFH‐1 genotype. The last section is the infection protocol coupled with the measurement of viral titer. © 2017 by John Wiley & Sons, Inc.

The human primary hepatocytes are ideal natural host cells for liver-targeting pathogens such as hepatitis B (Kaneko et al., 2016; , hepatitis C (Sa-Ngiamsuntorn et al., 2016) malarial parasite (Ng et al., 2015) and dengue viruses (Lang, Vera, Cheng, & Tang, 2016) . The difficulty in obtaining these cells and their limited life span restricted the study of long term host-pathogen interactions and xenobiotic metabolism. Hepatitis C virus is a single positive-stranded RNA virus belonged to the genus of Hepacivirus and Flaviviridae family (Simmonds et al., 2005) . Chronic HCV infection led to cirrhosis and hepatocellular carcinoma (Chisari, 2005 ). An estimated 130-150 million people globally have chronic HCV infection and there is no effective vaccine to protect against HCV. Recently, the treatment of HCV using direct-acting antivirals (DAA) drugs such as sofosbuvir and simeprevir could eradicate HCV infection. However, several DAA drugs resistance have been reported (Imhof & Simmonds, 2011; Jazwinski & Muir, 2011) . The development of effective HCV culture models is critical for designing efficacious anti-HCV strategies. The studies on HCV life cycle and anti-HCV drugs relied on human hepatocellular carcinoma cell lines such as Huh7 and their derivative clones. Only HCV genotype 2a (JFH-1) could be propagated from Huh7 derived cells (Catanese & Dorner, 2015; Wakita et al., 2005) . The application of hepatocellular carcinoma cells as a host for HCV could not fully mimic primary human hepatocytes. The genotype and phonotype of cancer cell are abnormal. Huh7 cells also lose their contact inhibition dissimilar to the primary hepatocytes which mostly present in quiescent stage. Most hepatocellular carcinoma cells usually lack several liver enzymes e.g., CYP450s, other phase I, II, and drug transporters that make them inadequate for the anti-HCV drug screening.

Human induced pluripotent stem cells (iPSCs) can be reprogramed from somatic cells through ectopic expression of Oct4, Sox2, Klf4, and c-MYC (Takahashi & Yamanaka, 2006; Takahashi et al., 2007) . These cells actively entered cellular division and can be differentiated into functional hepatocyte-like cell (HLCs) (Chun, Byun, & Lee, 2011 ) and other lineages. The applications of HLCs derived from either iPSCs or embryonic stem cells as natural hosts for HCV were recently reported (Schwartz et al., 2012; Si-Tayeb et al., 2012) . These differentiated cells expressed essential liver functions and achieved mature hepatocytes. HLCs also expressed known HCV host receptors involved in HCV entry (Claudin-1, Occludin, SR-BI, CD81) and supported complete life cycle of classical HCV genotype 2a up to 30 days (Sa-Ngiamsuntorn et al., 2016; Wu et al., 2012) . HLCs were promptly taken as HCV hosts. The infected cells could host full viral life cycle after the transfection/infection with HCVcc and HCVser. HLCs could sustain the replication of not only JFH-1 HCV but various wild-type HCV derived from patients' sera.

This unit describes overall procedures for generation of hepatocyte-like cell as a natural host hepatitis c virus production and drug metabolism. The unit begins with a Basic Protocol 1, which explains procedures for isolation human mesenchymal stem cell (MSC) from aspirated bone marrow. Basic Protocol 2 describes the further maintenance and culture of isolated MSCs. Lentiviral particles that carry the reprogramming factors (Oct4, Sox2, Klf4, and c-MYC are produced using plasmid co-transfection into HEK293T described in a Basic Protocol 3). To generate the iPSCs, MSCs are used as precursor cells for cellular reprogramming following the Basic Protocol 4. The iPSCS are characterized by various method such as alkaline phosphatase staining, immunofluorescent staining and pluripotent genes expression using reverse transcription PCR. Series of iPSCs characterization method are described in the Basic Protocol 5. Basic Protocol 6 describes hepatic induction of iPSCs to functional hepatocyte-like cell. Basic Protocol 7 describes the characterization of the differentiated cells using the following methods: Periodic acid-Schiff staining of glycogen, hepatocyte-selective gene expressions by real-time qPCR, CYP450s activities by luciferase-based assay and cellular hepatitis C receptors on HLCs by immunofluorescent staining. Basic Protocol 8 and 9 describe the applications of HLCs as a host for HCV infection and replication. Basic Protocol 10 demonstrates the infectivity titer of either HCVcc or HCVser in HLCs. At the moment, only HLCs can serve as host cells for wild-type HCV (HCVser).

The following procedures are performed in a Class II biological hazard flow hood or a laminar-flow hood.

NOTE: All solutions and equipment coming into contact with live cells must be sterile, and proper aseptic technique should be used accordingly.

NOTE: All incubations are performed in a humidified 37°C, 5% CO 2 incubator unless otherwise specified.

NOTE: All the cell culture reagents listed are stored, reconstituted and used as specified in the product data sheet supplied by the manufacturer unless specifically stated.

NOTE: Recombinant proteins and chemical inhibitors/activators should be stored at −20°C or −80°C after reconstitution.

Human mesenchymal stem cell (MSC) can be isolated from aspirated bone marrow of healthy donor. This protocol describes the procedure to separate the fraction of mononuclear cells using Ficoll density gradient centrifugation. Ficoll is a neutral, highly branched, high-mass, hydrophilic polysaccharide which dissolves readily in aqueous solutions. After centrifugation, the mononuclear cells are seeded and MSCs will appear within 7 days. Two weeks after seeding, MSCs display spindle-shaped morphology ( Figure 4A .13.1). The pure population of MSCs can be obtained after 1 to 2 passages of subculture.

Phosphate-buffered saline (DPBS) without calcium and magnesium Ficoll (GE Healthcare Life Sciences) 2. Transfer bone marrow aspirate (5 ml) into 50-ml centrifuge tube. Dilute bone marrow with PBS at a ratio of 1:4 to reconstitute the volume up to 20 ml.

3. To each of two 15-ml conical centrifuge tubes, add 3 ml of Ficoll -Hypaque reagent (IsoPrep) followed by the gentle overlay of the 10 ml of diluted bone marrow over the Isoprep. The solvent phase junction between the Isoprep layer and the bone marrow layer should not be disrupted. 4. Centrifuge the solution for 30 min at 1000 × g, 20°C with the brake off.

5. After centrifugation, the mononuclear cell layer would present as a white ring just above the interface between the Isoprep layer at the bottom and the diluted bone marrow layer on top. The white ring could be collected immediately using a sterile Pasteur pipette and transferred into a new 50-ml conical centrifuge tube.

Before collecting the white ring solution, remove the plasma solution in the upper layer by aspiration and gently pipette the white ring solution which contain the mononuclear cell into the conical centrifuge tube.

The cell density should be seeded at 10 6 -10 7 cells per one 75-cm 2 cell culture flask 9. Transfer the cell suspension into 75-cm 2 cell culture flasks and incubate the cell suspension in a humidified incubator with 5% CO 2 . Replace the culture medium for the first time on day 4 or 5 followed by every 3 to 4 days thereafter.

10. After 7 days, the adherent cells could appear and show spindle-shaped morphology when observing under an inverted microscope. The colony should be clearly observed on the culture surface. The possible contamination of the culture cell with some hematopoietic cells such as red blood cells and blood stem cell could be eliminated during successive cell passaging.

The MSC cell can be characterized by immunostaining for anti-CD105, anti-CD90, and anti-CD73 and the cell population can be analyzed using a flow cytometer (Wongkajornsilp, Sa-Ngiamsuntorn, & Hongeng, 2012) .

This protocol aims to propagate MSCs for further experiments or for frozen storage. The isolated MSCs can be enzymatically passaged following this protocol up to 10 times without the acquisition of cellular senescence. The maximum passage or life span of cultured MSCs could vary depending on the individual donor. The optimized time for harvesting MSCs was at the early passages (3 rd -5 th ) as a precursor cell for cellular reprogramming.

Human MSCs in 75-cm 2 flasks (see Basic Protocol 1) Phosphate-buffered saline (DPBS) without calcium and magnesium. 4. Inactivate the trypsin by adding 4 ml MSC culture medium with 10% FBS (α-MEM supplemented with 10% FBS, penicillin and streptomycin) to the flask and gently resuspend the detached cells. Transfer the reconstitution into a 50-ml conical centrifuge tube, and centrifuge for 10 min at 1000 × g, 20°C.

5. Discard the supernatant from the cell pellet and resuspend with 1-2 ml prewarmed MSC culture medium with 10% FBS (α-MEM supplemented with 10% FBS, penicillin and streptomycin).

6. Mix 10 µl of the cell suspension with 10 µl of trypan blue and count with a hemacytometer. Cell viability should be greater than 90%.

MSC cell density per 75-cm 2 flask should be around 2-5×10 6 cells.

7. Incubate the cells in 5% CO 2 at 37°C.

8. Replace the MSC culture medium twice a week and subculture once a week.

The MSCs at the early passage (i.e., 1 st to 4 th ) can be cryopreserved in liquid nitrogen for long-term use.

This protocol describes the production of lentiviral vectors for delivering the reprogramming genes (OSKM). To increase the safety of lentivirus, the essential components of viral production are split into multiple plasmids (three for 2 nd generation, for 3 rd -generation systems). The components of reprogramming vectors are as follows: (1) lentiviral transfer plasmid encoding Oct4, Sox2, Klf4, and c-MYC. These sequences are inserted between the LTRs region that enable host genome integration; (2) packaging plasmids; and (3) envelope plasmid. The procedure for producing infectious transgenic lentivirus consists of (a) co-transfection of three or four plasmids into HEK293T cells, (b) collection of conditioned medium containing the virus and (c) purification and concentration of the virus. The concentrated virus can then be used to infect the MSCs. Biosafety should always be considered with respect to the precise nature of experiments being performed. Your biosafety office can provide more information on your institution's best practices with regard to manipulating infectious virus. The NIH also has additional information on lentiviral safety considerations. The plasmids concentration can be measured using Nanodrop spectrophotometer and could be adjusted to 1 µg/µl or appropriate concentration.

3. Approximately 24 hr before transfection, seed HEK293T cells at a density of 4×10 6 cells in 10 ml DMEM, 10% FBS, 1× penicillin and streptomycin onto a 10-cm culture dish. Gently shake the cell culture dish side to side to evenly distribute the cells. Monitor the confluence daily and transfect the cells when the adherent cells are 70% to 80% confluent.

If cell detachment during transfection is observed, use cell culture dishes precoated with poly-D-lysine prior to the seeding of HEK293T.

Transfection of the lentiviral plasmids to the packaging cells 4. On the transfection day, gently remove the culture medium from the 10-cm cell culture dish and replace with 10 ml DMEM supplemented with 10% FBS, penicillin and streptomycin.

5. In a sterile 1.5-ml microcentrifuge tube, add 10 µg pRRL.PPT.SF.hOKSM. idTomato.preFRT or equivalent mixed thoroughly with 3.75 µg pMDLg/pRRE Gag, Pol plasmid, 3.75 µg pRSV-REV Rev plasmid, and 2.5 µg of pMD2.G vesicular stomatitis virus G envelope plasmid (Addgene) and adjust the total volume to 500 µl using Opti-MEM medium.

6. In a 1.5-ml microcentrifuge tube, add 440 µl of Opti-MEM medium and 60 µl X-tremeGENE HP DNA transfection reagent and mix by pipetting 2 to 3 times.

The undiluted X-tremeGENE HP DNA transfection reagent should be pipetted directly into Opti-MEM medium without any contact with the sides of the microcentrifuge tube as this may reduce transfection efficiency.

7. Gently mix the plasmid solution from step 5 with the solution from step 6 by pipetting and incubate the transfection reagent/DNA complex for 15 min at room temperature. Add the solution condition (1-ml) onto the 10-cm culture dish drop by drop using a micropipette to cover the entire culture area.

8. Incubating the transfection complex over the packaging cells on the cell culture dish in 5% CO 2 at 37°C overnight (16 to 18 hr).

9. Approximately 24 hr after transfection, replace the cell culture medium with 10 ml DMEM, 10% FBS containing 1× penicillin/streptomycin and incubate at 37°C, 5% CO 2 .

Isolation of lentiviral particles from the culture supernatant 10. At 48 hr after transfection, harvest the conditioned medium using a 20-ml syringe and filter through a 0.45-µm filter to remove cell debris. 11. To the concentrated lentivirus, add 1 volume of Lenti-X concentrator to 3 volume of clarified supernatant from step 10. Gently mix the solution by inversion. Incubate the mixture at 4°C for 1 hr. Centrifuge the solution for 1 hr at 1500 ×g, 4°C. After centrifugation, an off-white pellet will be visible.

The lentivirus in conditioned medium can be concentrated with sucrose gradient ultracentrifugation using 10% (w/v) sucrose for 4 hr at 90,000 × g.

Gently reconstitute the pellet in Dulbecco's phosphate-buffered saline (DPBS) and store up to 1 year at -80°C in single-use aliquots.

Please avoid freezing and thawing lentivirus more than one time. The freeze-thaw cycle reduces the viral infectivity titer.

Several types of cells have been used to generate iPSCs by transducing with reprogramming factors. The most common somatic cells that have been extensively reprogrammed are fibroblasts. However, human fibroblasts have some limitations such as a short life span, genetic instability, and requiring expansion into several passages before reprogramming. Human MSCs are multipotent stem cell-derived from aspirated bone marrow, which can be passaged up to 10 times without genetic instability and gene mutation. This protocol describes the procedures to infect MSCs with lentivirus carrying Oct4, Sox2, Klf4, and c-MYC including the selectable marker dTomato. The transduced MSCs can be observed by the red fluorescence of dTomato and forming colonies after 29 days post-transduction. Fully reprogramming colony can be selected by staining colonies with TRA-1-60 and observing the silencing of dTomato. After the 15 th passage, the iPSCs can be transferred to feeder-free culture in E8 medium and can be used as precursor cells for hepatocyte differentiation. 6-well plates 10-cm cell culture dishes Stereomicroscope 3.5-cm dishes Reprogramming MSCs to iPSCs 1. One day before the infection, seed MSCs at 1×10 5 cells on each well of a 6-well plate ( Fig. 4A .13.1A,B). Infect the MSCs with the lentivirus at a MOI of 0.5 through spinfection by centrifuging for 30 min at 1000 × g, 32°C, in MSC growth medium (α-MEM supplemented with 10% FBS, penicillin an streptomycin) containing 4 µg/ml polybrene.

2. After 16 to 18 hr post-infection, replace the medium with 2 ml MSC growth medium without polybrene, and maintain the infected MSCs in this culture medium for 5 days. Add 0.5 mM sodium butyrate into the culture medium on days 2 to 11 post-infection.

Adding sodium butyrate or valproic acid solution to the transduced MSCs could enhance cellular reprogramming.

3. On day 4, split the infected MSCs and plate from each 6-well plate onto 10-cm cell culture dishes pre-seeded with Mitomycin C-inactivated mouse embryonic fibroblast (i-MEF) feeder cells at a density of 3.5×10 4 cells/cm 2 . Maintain the infected cells in MSCs growth medium for 24 hr ( Fig. 4A .13.1C). Figure 4A .13.2 iPSC colonies were live-stained with TRA-1-60 antibody, a pluripotency surface marker. The iPSC colony was grown on MEF for 25 days after transduction (A) and live-stained with TRA-1-60 antibody followed by Alexa 488 conjugated goat anti mouse IgG. The TRA-1-60-positive colony was verified under fluorescence microscope (B). The dTomato disappeared in iPSCs (C). The iPSCs on Geltrex exhibited high nuclease-to-cytoplasm ratio with prominent nucleoli (D). Immunofluorescent staining for OCT4, SOX2, NANOG, TRA-160, TRA-1-81, and SSEA4 followed by the Alexa fluor 488 conjugated secondary antibody confirmed the identity iPSCs after the reprogramming from MSCs (E). Nuclei were localized by DAPI (blue). Scale bars = 100 µM. The expressions of pluripotency markers were determined by RT-PCR. iPSCs exhibited similar expression profile of pluripotent markers to that of embryonic stem cells (ESCs) (G). Pick the ES-like colonies using a stereomicroscope in the biosafety cabinet to avoid contamination. Transfer an individual colony from a single reprogramming cell onto each well of 6-well plate in order to get an identical iPSC line.

6. Perform preliminary identification of the reprogramming cells by staining the colony with anti-human TRA-1-60 antibody at a 1:100 dilution in iPSC medium for 30 min in CO 2 incubator. After the incubation, gently wash the colonies with 2 ml PBS, and then add Alexa fluor 488-conjugated goat anti-mouse IgG and/or IgM at a 1:1000 dilution and incubate for 30 min. Wash the colonies twice, each time with 2 ml iPSC medium ( Fig. 4A .13.2A-B).

7. Observe the TRA-1-60-positive colonies under a stereomicroscope and mark the colony by drawing a circle on the bottom of the plate with a permanent pen to further subculture. After the 15 th passage, the iPS colonies can be picked and maintained with feeder-free culture using Geltrex coated-plate and mTeSR1 medium or in house E8 medium with daily medium replacement ( Fig. 4A .13.2D).

After transferring iPSCs to feeder-free condition, cultured iPSCs in mTeSR1 and 10 µM Y-27632 should yield viable colonies.

8. Under feeder-free conditions, passage the iPSCs by incubating with diluted Versene solution (0.5 mM EDTA) for 2-5 min or until the round cells appear. Remove the EDTA solution and reconstitute the iPSC with mTeSR1 or E8 medium plus 10 µM Y-27632 before seeding onto a new Geltrex-coated 3.5-cm dish.

The iPSC cells should reach 80-90% confluence prior to subculturing. Screen the spontaneous differentiated cells using an inverted microscope. Mark and remove the colony before subculture. Avoid bringing iPSCs to 100% since spontaneous differentiation can ensue.

Human-induced pluripotent stem cell (iPSCs) can be characterized by several methods such as pluripotent gene expressions, alkaline phosphatase activity, silencing of exogenous reprogramming factors, immunostaining of pluripotent markers, karyotype analysis and in vitro and in vivo differentiation. However, all of these methods are timeconsuming and labor intensive. In this unit, we describe some recommended screening protocols of iPSCs. These include three fundamental methods for rapidly characterizing iPSCs: (1) the alkaline Phosphatase (AP) activity, (2) immunofluorescent staining, and (3) 1a. Culture iPSCs for 5 days prior to measuring AP activity, at low to medium cell density.

2a. On day 5, aspirate the medium and fix the iPSCs with 4% PFA fixing solution for 1 to 2 min.

3a. Aspirate the fixative and rinse with 1 ml 1× Rinse Buffer and then add enough Naphthol/Fast Red Violet Solution to fully cover each well (e.g., 0.5 ml for a well of a 24-well plate). Incubate for 15 min in the dark at room temperature.

4a. Aspirate the staining solution and rinse each well with 1 ml 1× Rinse Buffer. Cover the cells with 1× PBS to prevent drying and then count the number of colonies expressing AP (red iPSC colonies) using a phase-contrast inverted microscope ( Fig. 4A .13.2G).

1b. Culture iPSCs for five days prior to analyzing pluripotent proteins, at low to medium cell density. 3b. The primary antibodies used for the iPSC characterization are as follow: NANOG, SOX2, SSEA4, OCT4, TRA-1-60, TRA-1-81, alpha fetoprotein (AFP), alphasmooth muscle actin, and β-III tubulin.

4b. Dilute primary antibodies in blocking solution at 1:100, incubate with iPSC colonies overnight at 4°C, and then wash the colonies three times, each time with 1 ml of 0.1% Tween-20 in PBS. 

1c. Extract the total RNA from iPSCs using illustra RNAspin Mini Kit with DNase I treatment.

2c. Covert the 200 ng of total RNA to cDNA using oligo-dT primer and ImProm-II reverse transcription system following the manufacturer's instructions.

3c. Dilute cDNA to 1:10 ratio and use as a template for the PCR reaction. Mix 2 µl of diluted cDNA with the PCR master mix solution containing KAPA2G Fast HotStart ReadyMix PCR Kit with 5 µM of each pluripotent gene primers (see Table 4A .13.1).

4c. Amplify the PCR products with a thermal cycler using temperature condition as follows: 5c. Detect the specific amplification of PCR products using gel electrophoresis with 1% agarose gel ( Fig. 4A .13.2F).

In this protocol, we describe the procedure to derive hepatocyte-like cells (HLC) from iPSCs using direct differentiation. The differentiated cells develop a homogeneous population of hepatoblast-like cells, which can be differentiated to functional hepatocytes ( Fig. 4A.13.3A ). This protocol can be applied to differentiate the conventional hES cell lines into HLCs. The procedure uses defined culture medium devoid of serum and non-defined factors and contains four steps, which mimic embryonic liver development stages. The procedure begins with expansion of iPSCs in cell culture plate followed by the first stage differentiation protocol. The iPSCs are differentiated into definitive endoderm cells. In the second stage, differentiated cells are developed into anterior definite endoderm cells. During the third stage, the endodermal cells turned into hepatic progenitors. In the fourth stage, the HLCs undergo functional maturation and exhibit liver specific markers, such as albumin secretion, glycogen storage, cholesterol metabolism, Manipulation of Potency 4A.13.13 Bringing iPSCs higher than 60% confluence could decrease the homogenous endoderm differentiation and induce cell clumping. 3. Further maintain the cultured cells in 2 ml endoderm commitment medium DMEM/F12: IMDM (1:1), 2 mg/ml PVA, 2% (v/v) concentrated lipids, 100 ng/ml activin A, 100 ng/ml bFGF, 10 ng/ml BMP-4, 1× Insulin-Transferrin-Selenium, and 1 µM LY294002 for 24 hr.

Adjust the optimal LY294002 concentration from 1 µM to 10 µM, some previous publications use 10 µM LY294002. In our experiment, this concentration induced cell death.

4. Culture the endoderm-like cells in 2 ml anterior definitive endoderm differentiation medium: RPMI/B27 with 50 ng/ml activin A for 3 days with a daily medium replacement.

Anterior definitive endoderm is committed over a 3-day period with medium changes every 24 hr until the third day. Typical morphology of cells undergoing differentiation can be obtained (Fig. 4A.13.3A ).

5. Maintain the differentiated cells in 2 ml hepatic lineage specification medium (RPMI/B27, 20 ng/ml BMP-4 and 10 ng/ml FGF10) for 4 days with daily medium replacement.

6. Culture the differentiated cells in 2 ml HBM Basal Medium (HBM; 30 ng/ml oncostatin M and 50 ng/ml HGF) for 10 days with medium replacement every 2 days. 

To ensure that iPSCs achieve complete hepatic differentiation, this protocol selects some distinct markers to confirm hepatic phenotypes. Mature hepatocytes accumulate glycogen in cytoplasm and are measured using the Periodic Acid-Schiff staining (PAS) assay. The expression of selective hepatocyte markers e.g., albumin, α-fetoprotein, cytokeratin 18, G-6-PD, HNF-4α, tyrosine aminotransferase, and cytochrome P450 could be used to determine the maturation of HLC (Sa-ngiamsuntorn et al., 2011) . In this protocol, we describe the procedure used to evaluate the hepatic markers using quantitative real-time PCR to benchmark HLC against the primary hepatocyte. Cytochrome P450 activities can be measured using luciferase-based assay (Sa-ngiamsuntorn et al., 2016) . The resulting cells in this unit still express significant levels of α-fetoprotein and also express markers of adult hepatocytes such as albumin, α-fetoprotein, cytokeratin 18, G-6-PD, HNF-4α, and tyrosine aminotransferase. The CYP450s expression and activity increasingly responded to the prototypic inducers in the same fashion to primary hepatocyte. In the last section of this unit, we describe the protocol to detect hepatitis C host specific receptors such as Claudin-1, Occludin, SR-BI, CD81 using reverse transcription PCR and immunofluorescent staining. 2. Discard the culture medium and fix the adherent cells in 1 ml of 95% ethanol/5% formaldehyde for 1 min, and then rinse the cells under running tap water for 1 min.

3. Immerse the cells in periodic acid solution for 5 min, rinse the sample three times, each time with 1 ml dH 2 O, immerse the sample in Schiff's reagent for 15 min, and rinse with running tap water for 5 to 10 min.

4. Counterstain the samples with 0.5 ml Mayer's hematoxylin for 1 min, rinse the samples with water, and examine the samples under light microscope.

6. Immediately, construct cDNA from the total RNA using the ImProm-II reverse transcription system following the manufacturer's instructions.

The total mRNA can be stored for several weeks at −70°C. Immediately, converting mRNA to cDNA is highly recommend because mRNA is not stable at room temperature.

7. The hepatocyte markers and cytochrome P450 markers are albumin, α-fetoprotein, cytokeratin 18, G-6-PD, HNF-4α, tyrosine aminotransferase and major 7 CYPs isozymes. All gene-specific primers including a house keeping gene (GAPDH) are designed using vector NTI version 11.5 (Invitrogen). All primers are listed (Table 4A .13.2).

8. Amplify the specific genes using KAPA SYBR FAST qPCR Kits. In each reaction, mix 50 ng of cDNA with 15 µl of the master mix of the KAPA SYBR FAST qPCR kits and 5 µM of a pair of specific primers. Amplify the target DNA with a Mx3005P qPCR System using the following temperature profile: first step: 95°C for 3 min; second step: 40 cycles of 95°C for 10 sec, 60°C for 20 sec, and final step: melting curve analysis. Confirm PCR amplicons using size and melting curve analysis.

Agarose gel electrophoresis is needed to check the authenticity of the PCR products. If the researcher use SYBR green master mix from others suppliers, one should run no template control (NTC) to optimize the PCR condition.

9. Calculate gene expression levels using the Ct method and normalize to the endogenous GAPDH expression. Transform the Ct into fold change using the formula: fold change = 2 -Ct .

10. Culture HLCs, HepaRG, and primary human hepatocyte on the collagen type IVcoated 6-cm dish at a density of 10 6 cells/well. 11. Incubate the culture cells with a cocktail of 20 µM rifampicin, 50 µM omeprazole, 1 mM phenobarbital, and 88 µM ethanol. Incubate all treated cells for 48 hr with daily medium change.

12. Measure CYP1A1, CYP2B6, CYP2C9, and CYP3A4 enzyme activities in all cultured cells using the P450-glo 1A1, 2B6, 2C9, and 3A4 assays (V8751, V8321, V8791, V9001). After a 2-day incubation period, incubate the cells with Williams' Medium E supplemented with 100 µM Luciferin-CEE, Luciferin-2B6, Luciferin-H for 3 to 4 hr or 3 µM Luciferin-IPA for 30 to 60 min.

13. Transfer 50 µl of the medium to 96-well opaque white luminometer plate. Add the luciferin detection reagent to each well, incubate at room temperature for 20 min, measured with a spectrofluorometer.

14. The relative luminescence unit (RLU) could be calculated as follows: RLU= (LU treated-LU blank)/(LU untreated-LU blank).

15. Monitor cellular receptors essential for HCV infection such as Claudin-1, Occludin, SR-BI, and CD81 using quantitative RT-PCR and immunofluorescent technique. Seed mature HLCs on a 24-well plate and maintain until reaching 80% confluency in Williams' Medium E, 10% FBS.

16. Fix and stain HLCs with fluorescent-conjugated antibodies raised against Claudin-1, Occludin, SR-BI, or CD81 as described in the section "Detection of pluripotent markers using immunofluorescent staining" (Fig. 4A.13.3B ). 

The full-length genome of JFH-1 has been cloned into the pUC DNA vector under the transcription control of T7 promotor (Kato et al., 2001) . The length of pJFH-1 is ß12.4 kb and the pUC DNA vector contains the ampicillin resistance gene. The pJFH-1 plasmid can be transformed and propagated in E. coli in medium with 100 µg/ml ampicillin. To propagate the HCVcc, purified pJFH-1 DNA is linearized at the end of HCV sequence with the restriction enzyme XbaI to synthesize the genomic JFH-1 RNA from in vitro transcription. The HCV JFH-1 RNA is then transfected into Huh7 cells or HLCs to allow HCV replication and virion production. The virus released into the medium can be tittered with infectious virion as focus forming unit (ffu) per ml .

Huh7 and Huh7-derived hepatocytes (e.g., Huh7.5 and Huh7.5.1) have been used to produce HCV infectious particles up to 10 4 to 10 6 ffu /ml after transfection with JFH-1 RNA or infection with HCVcc. Huh7 and their derivatives are hepatocellular carcinoma isolated from a Japanese male with well-differentiated hepatocellular carcinoma (Nakabayashi, Taketa, Miyano, Yamane, & Sato, 1982) . HLCs derived from iPSCs can also host HCV production after transfection with JFH-1 RNA or infection with HCVcc and usually produce 10 6 to 10 7 ffu /ml. The advantages of HLCs as a natural host for HCV production/infection are their non-malignant origin and their capacity to produce higher HCV titer than those from classical Huh7-derived hepatocytes. In the following procedure, this unit describe the HCVcc propagation protocols using Huh7 cell and HLCs as hosts for viral production using liposome-based transfection. 

3. Reconstitute the total volume of linearized DNA solution to 400 µl using TE buffer, pH 7.5.

4. Add 500 µl buffered phenol (pH 7 to 8) and mix the sample vigorously using a vortex mixer.

Phenol and chloroform are hazardous and require use of protective gloves and eyewear.

5. Centrifuge the sample for 10 min at maximum speed, room temperature.

6. Pipette the upper aqueous solution containing linearized JFH-1 DNA into a new 1.5-ml microcentrifuge tube, then add one equal volume of 25:24:1 (v/v) phenol/chloroform/isoamyl alcohol and mix the sample vigorously using a vortex mixer.

7. Centrifuge the sample again for 10 min at maximum speed, room temperature.

8. Pipette the upper aqueous solution containing linearized JFH-1 DNA into a new 1.5-ml microcentrifuge tube, add one equal volume of chloroform, and mix the sample vigorously using a vortex mixer.

9. Centrifuge the sample again for 10 min at maximum speed, room temperature.

10. Pipette the upper aqueous solution containing linearized JFH-1 DNA into a new 1.5-ml microcentrifuge tube, add 1/10 volume of 3 M sodium acetate, pH 7.0 to achieve a final concentration of 0.3 M sodium acetate (add 44 µl of 3 M sodium acetate at pH 7.0 to 400 µl sample), and mix the sample vigorously using a vortex mixer.

11. Add one volume of isopropanol to the microcentrifuge tube and mix the sample vigorously using a vortex mixer. The DNA sample could be precipitated using 2 volumes of ethanol. Depending on sample volume and maximum tube capacity, one volume could also precipitate the DNA using 2 volumes of ethanol.

12. Incubate the plasmid solution for 1 hr at −20°C to allow plasmid DNA precipitation. To achieve complete precipitation, the overnight incubation is recommended for DNA less than 5 µg being digested.

13. Precipitate the DNA by centrifuging for 30 min at maximum speed,4°C, remove the isopropanol, and wash the pellet with 500 µl of 75% ethanol.

14. Centrifuge the DNA sample for 5 min at maximum speed, room temperature. Discard 75% ethanol, wash the pellet with 500 µl of 100% ethanol, and centrifuge the DNA sample for 5 min at maximum speed, room temperature. Discard 100% ethanol and aspirate the leftover liquid that may present on the tube. Air dry the DNA pellet at room temperature.

15. Reconstitute the DNA pellet in nuclease-free water and measure DNA concentration using Nanodrop spectrophotometer. The reconstituted volume of nuclease-free water depends on the amount of DNA being digested.

Normally, one microgram per microliter is recommended. The DNA sample could be stored at −20°C for further use.

16. Transcribe the JFH-1 mRNA from linearized plasmid using TranscriptAid T7 High Yield Transcription Kit following the manufacturer's instructions.

17. Combine the following reaction components at room temperature in the order as described: In a new 200-μl PCR tube, mix 4 µl 5× TranscriptAid Reaction Buffer, 8 µl ATP/CTP/GTP/UTP mix, 1 µg linearized JFH-1 DNA and 2 µl TranscriptAid enzyme mix. Adjust the total volume to 20 µl with DNase/RNase-free distilled water.

18. Mix the sample thoroughly by hand, spin down to collect all drops, and incubate for 2 hr at 37°C.

19. Purify the JFH-1 RNA using chloroform extraction and ethanol precipitation of RNA. Add 115 µl DNase/RNase-free distilled water and 15 µl of 3 M sodium acetate solution, pH 5.2, into the 20 µl solution from step 18 and mix thoroughly using a vortex mixer.

Purification methods include but are not limited to these methods. All methods have their particular benefits and all are convenient and effective ways to recover RNA. The authors usually employ phenol/chloroform extraction and isopropanol precipitation.

20. Extract the JFH-1 RNA with an equal volume of 1:1 phenol (pH 4.7)/chloroform mixture and then add another equal volume of chloroform. Collect the aqueous phase and transfer the solution into a new 1.5-ml tube.

21. Add 2 volumes of ethanol to the sample to precipitate JFH-1 RNA. Incubate at −20°C for at least 30 min and collect the pellet by centrifugation.

22. Discard the supernatant and rinse the pellet with 500 µl cold 70% ethanol and reconstitute the RNA with 20 µl of DNase/RNase-free distilled water.

23. Store the JFH-1 RNA at −20°C or −70°C for long-term storage up to 6 months.

24. At 2 days prior to transfection, seed 1.5 × 10 6 HLCs or Huh7 cells onto 10-cm cell culture dish, maintain the culture cells in 10 ml DMEM/F12, 10% FBS, with 1× streptomycin and penicillin. The optimum cell number is depending on the number of transfections to be performed. Each transfection will require 4 × 10 6 cells. On a 10-cm dish at 80% confluency, HLCs and Huh7 are approximately 5 × 10 6 cells.

25. On the transfection day, gently remove the culture medium from the 10-cm cell culture dish and replace with 10 ml DMEM, 10% FBS.

26. In a sterile 1.5 ml microcentrifuge tube, mix 15 µg JFH-1 RNA with Opti-MEM medium and adjust the total volume to 500 µl with Opti-MEM medium.

27. In another 1.5 ml microcentrifuge tube, add 440 µl Opti-MEM to a tube and pipet 60 µl X-tremeGENE HP DNA transfection reagent directly into the Opti-MEM.

Do not pipette X-tremeGENE HP DNA transfection reagent directly into microcentrifuge tube because the transfection efficiency will decrease.

28. Gently mix the plasmid solution from step 26 with the solution from step 27 by pipetting and incubating the transfection reagent/DNA complex for 15 min at room temperature. Add the solution condition (1 ml) onto the 10-cm culture dish drop by drop using a micropipette to cover the entire culture area.

to ensure that the plasmid solution covers the entire culture area.

29. Incubate the cell culture dish overnight (16 to 18 hr) in a 37°C, 5% CO 2 incubator.

30. Approximately 24 hr after transfection, replace the cell culture medium with 10 ml DMEM/F12, 10% FBS, 1× penicillin/streptomycin and incubate at 37°C, 5% CO 2 .

31. Collect the conditioned medium every 3 days and keep at 4°C. Conditioned medium can be harvested within 2 weeks after transfection.

32. Clarify the conditioned medium containing HCVcc by centrifuging for 10 min at 500 × g, 4°C, to remove cell debris, and filter the supernatant through a 0.45-µm cellulose acetate filter.

33. Concentrate HCVcc to 5× using sucrose gradient ultracentrifugation. Briefly mix one volume 10% sucrose solution with 4 volumes conditioned medium, and then centrifuge for 2 hr at 100,000 × g, 4°C. Discard the supernatant and collect the HCVcc pellet.

34. Transfer the reconstituted HCVcc into an individual 1.5-ml microcentrifuge tube for a single freeze/thaw cycle and store up to 1 year at −70°C for further use.

HLCs and Huh7 cells can host HCVcc derived from JFH-1 RNA and produced infectious virions. Depending on host cells and HCV genotypes, maximal titers could be obtained on day 7 to day 12 from HCVcc-infected HLCs and Huh7 cells with an MOI of 0.01 ffu/cell. This protocol aims to produce HCVcc starting from the infectious virions, instead of from the classical transfection with JFH-1 RNA. The advantages of this infection protocol over the classical transfection protocol consist of: (1) the infection protocol is simplified;

(2) the infection protocol spends less time and resources; and (3) the infection protocol allows higher titer of HCVcc. The protocol described in this unit has been optimized to generate infectious JFH-1 HCVcc from HLCs and Huh7 cells. Huh7 cells normally produce HCVcc with titers ranging from 10 4 -10 6 ffu/ml. HLCs produced higher titers with a range from 10 7 -10 8 ffu/ml. Huh7 cells were incapable for hosting HCV derived from patient serum (HCVser), but HLCs can readily host HCVser that lead to rising HCV titers to 10 4 -10 6 ffu/ml (Fig. 4A .13.4C-D). 3. The infected cells should reach 90% confluency within 1 or 2 days post-infection. Collect the conditioned medium and transfer into a 50-ml conical tube, wash cell once with 5 ml PBS and trypsinize the cells using 0.05% trypsin-EDTA in PBS. Add 5 ml DMEM/F12, 10% FBS to inhibit the trypsin activity.

4. Reconstitute the trypsinized cells to a final volume of 10 ml with DMEM/F12, 10% FBS and transfer to the conical tube containing the conditioned medium. Adjust the volume to 50 ml by add 30 ml of DMEM/F12, 10% FBS into the conical tube.

5. Seed 2×10 7 infected Huh7 cells or HLCs in 10 ml of DMEM/F12, 10% FBS, 1× streptomycin and penicillin onto 10-cm cell culture dishes (10 ml/dish).

6. Observe the cytopathic effect (CPE) in the HLC and Huh7 cells. HCVcc-infected cells usually exhibit CPE on day 6 to 8 post-infection. Collect the conditioned medium daily and store at 4°C prior to ultracentrifuging. The maximum JFH-1 viral titer are usually achieved on day 7 to 12 post-infection.

7. After harvesting HCVcc, add 10 ml of DMEM/F12, 10% FBS, 1× streptomycin and penicillin to each dish and bring the culture cells to incubator.

Conditioned culture medium can be harvested every 3 days into conical centrifuge tubes. Virus-containing medium can be stored at −80°C for future determination of viral titers.

8. Clarify the conditioned medium containing HCVcc by centrifuging for 10 min at 500 × g, 4°C. To remove cell debris, filter the supernatant through a 0.45-µm cellulose acetate filter.

9. Concentrate HCVcc to 5× using sucrose gradient ultracentrifugation. Briefly, mix one volume 10% sucrose solution with 4 volumes conditioned medium, centrifuge for 2 hr at 100,000 × g, 4°C, discard the supernatant, and collect the HCVcc pellet.

10. Transfer the reconstituted HCVcc into several 1.5-ml microcentrifuge tubes to allow a single freeze/thaw cycle, and store up to 1 year at −70°C for further use.

Viral infection can be measured by several techniques. For cytolytic viruses such as coronavirus and herpes viruses, the most frequently used technique is plaque assay on cell culture in monolayers using inert overlay or non-inert overlay with methylcellulose or agarose (Cooper, 1961) . Viral infectivity titers are calculated as plaqueforming units (pfu/ml) based on the number of plaques presented in the cell monolayer culture. However, HCVcc is a non-cytolytic virus and does not form plaques on HLC monolayers. The HCVcc could form a small foci of HCV protein (e.g., core antigen), which can be detected by immunofluorescent staining of 4% PFA fixed infected cells in monolayers. The number of positive cells is calculated for HCV infectivity titers as focus-forming units (ffu/ml). The protocol described in this unit uses immunofluorescent staining to determine the HCV core antigen in the HCV-infected cells (Zhong et al., 2005) .

Hepatocyte - 12. Calculate HCV titer as focus-forming units ffu/ml under a fluorescence microscope or from a photograph (Fig. 4A.13.4B ). Select triplicate culture wells with an adequate number of foci to perform a reliable count.

The authors prefer to select wells with 10 to 50 distinct foci.

13. Using the average number of foci in the triplicate wells, calculate the titer in ffu/ml using the following formula:

Titer (ffu/ml) = foci number × (1/dilution factor of HCV)

× (1/volume plated in ml)

For example, if an average of 30 foci were observed at 10 2 dilution after infection with 50 µl of HCVcc, then the ffu/ml = 30 ffu × (1/10 -2 ) × (1/0.05 ml) = 6×10 4 ffu/ml.

14. Collect the leftover HCV-positive sera from chronic HCV patient. The collection of leftover blood specimen should receive an approval from the IRB. Select the serum from HCV patient with HCV load > 10 6 IU/ml to infect HLCs.

Carrying infectious specimens should follow the NIH or institutional guidelines.

15. For HCVser infection, seed HLCs on a 6-well plate in Williams' Medium E, 10 % FBS until reaching 80% confluency.

16. Pretreat HLCs with 5 µM α-tocopherol for 24 hr prior to incubation with HCVser. Add 50 µl of patient serum in 2 ml culture medium.

Pretreated HLCs with α-tocopherol lowers lipid peroxidation from patient serum and enhances HCVser infectivity.

17. After 24 hr incubation, wash the HLCs five to six times, each time with 1 ml of 0.1% BSA in PBS, and reconstitute with 2 ml Williams' Medium E, 10 % FBS. Replace and collect conditioned medium twice a week for one month.

The maximum titers should be obtained on day 7 to 14 from HLCs infected with HCVser.

18. Observe the cytopathic effect (CPE) in HLCs. HCVser-infected cells usually exhibit CPE on day 7 to 9 post-infection. Syncytial cells would form within 2 weeks after infection (Fig. 4A.13.4A ).

19. Pool the conditioned medium in a 50-ml conical centrifuge tube and filter through a 0.45-µm filter to remove cell debris.

Use deionized, distilled water in all recipe (unless otherwise indicated).

400 ml phosphate-buffered saline (PBS) without calcium and magnesium, prepare with deionized or double-distilled H 2 O without Ca 2+ and Mg 2+ ) 15 g bovine serum albumin, Fraction V 2.5 ml 10% (v/v) Triton X-100 (Sigma, cat. no. X100) 50 ml fetal bovine serum (FBS; 10% final), heat-inactivated (56°C for 30 min) Bring to 500 ml total volume with PBS (without CaCl 2 and MgCl 2 ) Filter sterilize using a 0.2-μm cellulose acetate filter Store up to 1 year at 4°C 

Preparing by add 10 g of methylcellulose (Methocel MC, Fluka Bio-Chemika, cat. no. 64625) to 500 ml water in a sterile 1-liter bottle containing a stir bar. Stir at 4°C until methylcellulose partially goes into solution (ß4 hr). Do not heat; methylcellulose will only dissolve in cold solutions. Sterilize by autoclaving. Allow solution to return to room temperature (methylcellulose will solidify), shake vigorously to break up clumps, and transfer to 4°C overnight. It will not be possible to stir the methylcellulose, but it will gradually go into solution. Store up to 6 months at 4°C.

MEM Alpha modification containing: 10% (v/v) heat-inactivated fetal bovine serum (FBS) 2 mM L-glutamine or 1× GlutaMAX 1× penicillin/streptomycin (add from 200× stock) Store up to 4 weeks at 4°C

20 g paraformaldehyde (PFA), 400 ml phosphate-buffered saline (PBS) without calcium and magnesium. Adjust pH to 7.4 with 10 N NaOH (PFA will not well dissolve into solution until pH is 7.4). Aid dissolution by heating solution in fume hood (do not let solution rise above 65°C). Bring to 500 ml total volume with DPBS (without CaCl 2 and MgCl 2 ). Filter sterilize using a 0.22-μm filter, wrap in aluminum foil, and store up to 1 year at 4°C.

Reconstitute lyophilized bFGF to a final concentration of 10 µg/ml in PBS containing 0.1% (w/v) bovine serum albumin (BSA). Store at −80°C according to manufacturer's instructions. Store up to 1 year at −80°C.

490 ml RPMI 1640 10 ml B27 5 ml NEAA 5 ml Penicillin/streptomycin Medium should to be warmed to 37°C prior to use. Store up to 3 weeks at 4°C

Dissolve LY294002 and CHIR99021 in dimethyl sulfoxide (DMSO) at a stock concentration of 10 mM. Store up to 1 year at −80°C.

only carried less CYP450 expression than that of the primary hepatocytes, but retained several fetal hepatocyte markers. Recently, we reported a new model of natural HCV infection using HLCs and identified the crucial factors SEC14L2, an α-tocopherol transfer protein required for HCVser infection. These HLCs reproducibly express overall hepatic functions comparable to the primary human hepatocyte (Sa-Ngiamsuntorn et al., 2016) .

Collecting the bone marrow from a healthy donor could be performed by certified surgeons. All procedures should receive an approval from IRB. Immediately preserve the bone marrow in heparin solution to prevent blood coagulation. Do not shake the tube or disrupt the solvent interface between the Isoprep solution and the diluted bone marrow to avoid low MSC yield.

During trypsinization, do not incubate MSC in trypsin/EDTA longer than 10 min. Over incubation compromises cell viability after cell passaging. The optimal split ratios are between 1:3 to 1:6. MSCs in the early passage could be cryopreserved in liquid nitrogen. Do not use MSC in the late-passage or in senescence stage (passage >10) as a cell source for reprogramming. MSCs in late-passage usually have unstable karyotype.

All of the following steps in this unit should be performed in a class II tissue culture cabinet. Lentivirus requires the use of a Biosafety Level 2 facility. Pseudotyped lentiviruses packaged from HIV-1-based vectors are capable of infecting human cells. Handling with infectious virus should follow the institutional guidelines for biosafety. The following information is a brief description of Biosafety Level 2.

1. Practices: -Standard microbiological practices -Limited access to work area -Biohazard warning signs posted -Minimize production of aerosols -Decontaminate potentially infectious wastes before disposal -Use precautions with sharps (e.g., syringes, blades) -Biosafety manual defining any needed waste decontamination or medical surveillance policy 2. Safety equipment:

-Biological Safety Cabinet, preferably a Class II BSC/laminar flow hood (with a HEPA filter) used for all manipulations of agents that cause splashes or aerosols of infectious materials; exhaust air is uncirculated -PPE: protective laboratory coats, gloves, face protection as needed 3. Facilities:

-Autoclave available for waste decontamination -Chemical disinfectants available for spills Lentiviral plasmids should be prepared with molecular biology grade reagents to avoid chemical contamination. Each plasmid should be verified with restriction map analysis.

After being passaged and split at a ratio of between 1:6 to 1:10 for 6 to 8 days, hPSCs will be 80% confluent and ready for passaging. The GSK-3 inhibitor (CHIR99021) is added only on the first day of differentiation. The endodermal differentiation takes 3 days. Replace the differentiation medium every 24 hr until the third day. Hepatic differentiation takes 4 days. Hepatic maturation can be monitored with the expression levels of HNF-4α, AFP and albumin using quantitative real-time PCR. Particularly, HNF-4α expression should be expressed in 90% of the cell population. Additional incubation with 1% DMSO in Williams' Medium E could increase CYP450s expression. Authors have also found that the quality of growth factors and reagents being purchased commercially can affect the efficiency of differentiation.

The critical point for the production of infectious HCVcc using in vitro-transcribed HCV RNA was the quality and quantity of fulllength HCV RNA genome. The JFH-1 expression plasmid vector contains a T7 promotor that drives the transcription of an approximate 9.6 kb RNA genome. However, the transcription should be optimized to perfect the synthesis of large HCV transcript. The authors recommend that the in vitro-transcription should be monitored with gel electrophoresis to ensure RNA quality. The incidence of a large smear of RNAs in different sizes rather than

Animal models for hepatitis C. Current Topics in Microbiology and Immunology

Efficient replication of hepatitis C virus genotype 1a RNAs in cell culture

Advances in experimental systems to study hepatitis C virus in vitro and in vivo

Unscrambling hepatitis C virus-host interactions

Induced pluripotent stem cells and personalized medicine: Current progress and future perspectives

Viral hepatitis: A new HCV cell culture model for the next clinical challenges

The plaque assay of animal viruses

In vitro infection of primary human hepatocytes by HCV-positive sera: Insights on a highly relevant model

From skin cells to hepatocytes: Advances in application of iPS cell technology

Genotype differences in susceptibility and resistance development of hepatitis C virus to protease inhibitors telaprevir (VX-950) and danoprevir (ITMN-191)

Directacting antiviral medications for chronic hepatitis C virus infection

Human induced pluripotent stem cellderived hepatic cell lines as a new model for host interaction with hepatitis B virus

Sequence analysis of hepatitis C virus isolated from a fulminant hepatitis patient

Modeling dengue virus-hepatic cell interactions using human pluripotent stem cell-derived hepatocyte-like cells

Complete replication of hepatitis C virus in cell culture

Unravelling hepatitis C virus replication from genome to function

Growth of human hepatoma cells lines with differentiated functions in chemically defined medium

Human iPSC-derived hepatocyte-like cells support Plasmodium liver-stage infection in vitro

Hepatocyte-like cells derived from induced pluripotent stem cells

Upregulation of CYP 450s expression of immortalized hepatocyte-like cells derived from mesenchymal stem cells by enzyme inducers

A robust model of natural hepatitis C infection using hepatocyte-like cells derived from human induced pluripotent stem cells as a long-term host

SEC14L2 enables pan-genotype HCV replication in cell culture

Modeling hepatitis C virus infection using human induced pluripotent stem cells. Proceedings of the National Academy of Sciences of the United States of America

Hepatocyte-like cells differentiated from human induced pluripotent stem cells (iHLCs) are permissive to hepatitis C virus (HCV) infection: HCV study gets personal

Consensus proposals for a unified system of nomenclature of hepatitis C virus genotypes

Cell culture systems for hepatitis C virus

Induction of pluripotent stem cells from adult human fibroblasts by defined factors

Induction of pluripotent stem cells from mouse embryonic and adult fibroblast cultures by defined factors

Production of infectious hepatitis C virus in tissue culture from a cloned viral genome

Development of immortalized hepatocyte-like cells from MSCs

Productive hepatitis C virus infection of stem cell-derived hepatocytes reveals a critical transition to viral permissiveness during differentiation

Use of human hepatocyte-like cells derived from induced pluripotent stem cells as a model for hepatocytes in hepatitis

Robust hepatitis C virus infection in vitro. Proceedings of the National Academy of Sciences of the United States of America

The authors would like to thank Prof. Takaji Wakita (National Institute of Infectious Diseases, Japan) for his generous gift of the fulllength JFH-1 HCV plasmid. This study was funded by the research grants from Mahidol University awarded to S. Hongeng; and from the Thailand Research Fund (TRF) separately awarded to A. Wongkajornsilp and K. Sa-ngiamsuntorn. A. Wongkajornsilp is a recipient of Chalermprakiat grant of the Faculty of Medicine Siriraj Hospital, Mahidol University.

Hepatitis C virus is a tropic positivestranded RNA virus causing acute and chronic hepatitis that could develop into hepatocellular carcinoma (Chisari, 2005) . HCV infection is the leading cause of life-threatening chronic liver disease and affects ß3% of the world population (Gondeau et al., 2014) . Current in vivo model of HCV is limited to humans and chimpanzees owing to ethical concerns, economics, and the technical boundaries of in vivo experiment (Billerbeck, de Jong, Dorner, de la Fuente, & Ploss, 2013) . Different in vitro models that support the entire HCV life cycle (entry, replication, assembly, release) and the host reacting innate immune response have been demonstrated (Steinmann & Pietschmann, 2013) . However, our current knowledge of HCV life cycle is largely dependent on the molecular clone JFH-1 (HCV genotype 2a) that replicates in a few hepatocellular carcinoma cell lines with resulting infectious particles (HCVcc) production (Saeed et al., 2015) .Hepatocytes can host HCV infection and allow infectious viral production (Zhong et al., 2005) . Since the discovery of HCV in 1989, a major burden impeding HCV study has been the lack of robust hepatocyte culture model to grow HCV derived from patient serum (HCVser) (Saeed et al., 2015) . The significant improvement has been made with the isolation of a HCV genotype 2a from Japanese patient suffering with fulminant hepatitis (JFH-1). The JFH-1 HCV together with human hepatocellular carcinoma cell line, Huh7 or its derivatives brought a promising cell culture model to study the entire HCV life cycle (Wakita et al., 2005) . The application of hepatocellular carcinoma as a natural HCV host could not completely mimic primary human hepatocyte. Cancer cells usually lack some specific factors necessary for the repli-cation of HCV derived from patient serum. The newly identified factor, SEC14L2 promotes HCV infection by enhancing vitamin E-mediated protection against lipid peroxidation. The exogenous expression of SEC14L2 in Huh7.5 cell line allowed HCVser to replicate in hepatocellular carcinoma cell line (Colpitts & Baumert, 2015) . Even though the lacking of essential host factor for HCVser infection was solved, the impairment of various liver functional enzymes such as CYP450s and other phase I, II, and III drug metabolizing enzymes make the hepatoma cells awkwardly unfitt] for the assessment of anti-HCV drug interaction and metabolism (Blight, McKeating, Marcotrigiano, & Rice, 2003) .Human-induced pluripotent stem cell (iPSC) can be generated from the somatic cells using exogenous expression of the reprogramming factors (Oct4, Sox2, Klf4, and c-MYC). The iPSCs can differentiate into other cells, thus serve as a new model for drug discovery, disease modeling, and toxicity assessment (Greenbaum, 2010) . Recently, several investigators reported that iPSC can develop into functional hepatocyte-like cell (HLCs) that exhibited various functions associated with mature hepatocytes (Roy-Chowdhury, Wang, Guha, & Roy-Chowdhury, 2016). The applications of HLC derived from pluripotent stem cell as a natural host for HCV have been reported (Yoshida et al., 2011) . Differentiated HLCs exhibited important liver functions and achieved closely mature hepatocytes, including α-fetoprotein, albumin, phase I and phase II drug metabolizing enzymes. Importantly, HLCs also expressed known HCV host receptors involved in HCV entry (Claudin-1, Occludin, SR-BI, CD81) and supported entire life cycle of HCV genotype 2a up to 21 d (Wu et al., 2012) . Nonetheless, the maturity, homogeneity and long-term stability of these HLCs have not been revealed. The HLCs not a single band (with minimal smear of incomplete products) would indicate degradation or incomplete in vitro transcription. This could negatively affect intracellular HCV RNA replication after the transfection. The treatment with an RNase inhibitor and the optimization of incubation time during the transcription can improve the integrity of the HCV RNA genome. If longer RNA strand are detected, it might indicate that the plasmid DNA is not completely linearized and can interfere the transcription of the desired product. This problem can be resolved using either the linearized template DNA band prepared from agarose gel electrophoresis or another RNA template.

The most important factor in the generation of high-titer HCV stocks is the quality of host cells during production. Under ideal cellular conditions, Huh7 cell should produce JFH-1 HCVcc titers up to 10 5 ffu/ml, while HLCs could achieve the titers between 10 6 -10 7 ffu/ml. However, mycoplasma contamination, non-optimized cell density, varied lots of serum and chemical reagents can negatively impact HCVcc titers. After treating mature HLCs with 1% DMSO, passaging HLCs is not possible because DMSO would induce growth arrest. These cells carry the hepatic markers for months and closely mimic the primary human hepatocyte.

Only HLCs and Huh7.5 cells expressing SEC14L2 allow HCV production after being infected by patient serum (HCVser). The infectivity can be enhanced using 5-10 µM α-tocopherol pre-treated host cells or adding α-tocopherol together with the serum during the infection process. The lipid oxidation in lipoprotein particles destroys the envelope of HCVser. This lipid peroxidation could be prevented using α-tocopherol. The titer of HCV particles derived from patient serum typically was 10 4 -10 5 , and this was significantly inferior to transfected host cell with JFH-1 HCV RNA. The HCV particles should be stored at -70°C for long-term usage in a single use aliquot to avoid several freeze/thaw cycles.

To ensure the reproducibility and reliability of the future experiments, a single HCVcc stock sufficient to complete the entire experiment should be produced and the kinetics of infection should be evaluated. The HCV stock and handling techniques should also be optimized.

HCV is typically described as a noncytolytic virus. HCVcc and HCVser infected HLCs exhibit cytopathic effect (CPE) as identified by decreasing cell growth and roundshaped morphology with syncytial formation. The levels of CPE appeared differently among different HLCs, Huh7, and their derivative clones. The beginning of CPE frequently coincides with maximal viral titer. Therefore, collecting HCV particles during the initial onset of HCV-induced CPE is recommended. CPE usually appear in 2 weeks after the transfection with HCV RNA or infection with HCVser.

The series of protocols presented in this unit describe the production of functional hepatocyte-like cell as host cells for hepatitis C (HCV) studies. The procedure comprises three major stages: (1) the reprogramming of MSCs to iPSCs; (2) the differentiation of iPSCs to mature HLCs; and (3) the infection of HLCs with HCV. The minor protocols also describe the characterization and detection of iPSCs, HLCs, HCV host cell receptors and HCV titer including the production of HCV infectious particles. Successful reprogramming of MSCs to iPSCs establishes 2 -3 stable iPSC lines and these cells can be further differentiated into hepatic and other lineages. The hepatic induction protocol can generate expandable immature HLCs from iPSCs. These cells can be readily induced to functional HLCs using 1% DMSO and the defined condition. The mature HLCs express all hepatic markers, albumin, AFP, CK18, TAT, major CYP450s enzyme, and HCV cell receptors. Following the differentiation protocol should generate 10 7 mature hepatocytes from 6 × 10 5 iPSCs on a 10-cm dish.Production of HCV in HLCs cells using either transfection of in vitro-transcribed JFH-1 RNA or the infection of Huh7 cells with HCVser should yield titers between 10 4 -10 7 ffu/ml. Maximal JFH-1 titers in HLCs should be achieved on day 18 post transfection or day 12 post infection. On day 3 post-infection, HLCs are fixed and stained with anti-HCV protein (HCV core antigen). Numerous positive foci could be detected in cytoplasm of clusters of 5 to 10 cells using immunofluorescent straining.

The preparation of the primary culture of MSC from the aspirated bone marrow should take 2 weeks. During the 2 nd -4 th passage, MSCs which have been passaged one a week should be ready for reprogramming to iPSCs. It should take approximately 3 weeks before the transfection. The preparation of lentiviral plasmid from E. coli culture frequency takes 3 to 4 days to get purified plasmid DNA. The production of lentivirus carrying polycistronic OSKM takes one week starting from seeding HEK293T until the purification of the lentiviral particles. Reprogramming MSC to iPSC takes 2 to 3 months to achieve stable iPS clones. Differentiating iPSCs to immature HLC takes 27 days and mature HLCs can be yielded after incubation with 1% DMSO for a week. The production of HCVcc from HCV RNA should take 2 to 3 weeks, starting from linearizing JFH-1 plasmid until concentrating HCVcc. The assessment of HCV titer would start at 2 to 3 weeks after infecting HLCs with HCVcc or HCVser.

The authors declare that there are no conflicts of interest.